Page 54 - Drug Class Review

Final Report Update 1 Drug Effectiveness Review Project

51. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible
galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg
Psychiatry 2001;71(5):589-95.
52. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month,
randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study
Group. Neurology 2000;54(12):2269-76.
53. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild
to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine
International-1 Study Group. BMJ 2000;321(7274):1445-9.
54. Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose comparison in
patients with Alzheimer's disease. Int J Geriatr Psychiatry 2001;16(9):852-7.
55. Corey-Bloom JR, Anand JV, Veach J, and ENABSG. A randomized trial evaluating the
efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor,
in patients with mild to moderately severe Alzheimer's disease. International Journal of
Geriatric Psychopharmacology 1998;1:55-65.
56. Agid Y, Dubois B, Anand R, Gharabawi G. Efficacy and tolerability of rivastigmine in
patients with dementia of the Alzheimer type. Current Therapeutic Research, Clinical &
Experimental 1998;59(12):837-845.
57. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and
safety of rivastigmine in patients with Alzheimer's disease: international randomised
controlled trial. BMJ 1999;318(7184):633-8.
58. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled
trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA 1992;268(18):2523-
9.
59. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-
to-severe Alzheimer's disease. N Engl J Med 2003;348(14):1333-41.
60. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine
treatment in patients with moderate to severe Alzheimer disease already receiving donepezil:
a randomized controlled trial. JAMA 2004;291(3):317-24.
61. Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, et al. The
efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease.
Neurology 2004;63(2):214-9.
62. Loy C, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev
2004(4):CD001747.
63. Markowitz JS, Gutterman EM, Lilienfeld S, Papadopoulos G. Sleep-related outcomes in
persons with mild to moderate Alzheimer disease in a placebo-controlled trial of
galantamine. Sleep 2003;26(5):602-6.
64. Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral
disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am
J Psychiatry 2004;161(3):532-8.
65. Galasko D, Kershaw PR, Schneider L, Zhu Y, Tariot PN. Galantamine maintains ability to
perform activities of daily living in patients with Alzheimer's disease. J Am Geriatr Soc
2004;52(7):1070-6.
66. Tai CT, Liu CK, Sung SM, Pai MC, Hsu CY. The safety and efficacy of Exelon in
Alzheimers patients: A multicenter, randomized, 26 week study in Taiwan. International
Journal of Neuropsychopharmacology 2000;3 S 1:S 356.

Alzheimer's Drugs Page 54 of 205